Authors: Prof. Dr. Matthias Schonermark, Chief Strategy Officer & Sebastian Vinzens, Senior Medical Writer

The first EU JCA should not be read as a verdict on one product alone. It is a diagnostic of the new European access environment: a public map of where comparative evidence exists, where it is absent, and where fragile estimates may still become national reimbursement anchors. 

The Empty Grid: What Europe’s First JCA Really Tells Us About Launch Readiness 

The first EU Joint Clinical Assessment (JCA) has arrived, and the temptation is to read it as a technical milestone: the first report, the first template in use, the first test of the new machinery. That would miss the more important point. The tovorafenib JCA is not only an assessment of one medicine in a rare paediatric oncology indication. It is the first public stress test of the distance between regulatory evidence, comparative value, and national reimbursement reality in the new European HTA environment. 

The most striking image is the grid itself. One product. A broad regulatory indication. Eight PICO questions. Yet most of the grid remains essentially empty from a comparative evidence perspective. For several PICOs, no comparative results were submitted because no comparator data were available. Only one core comparative analysis, PICO 5 versus dabrafenib plus trametinib in patients over one year with BRAF V600E mutation, entered the JCA report as a relevant relative-effectiveness comparison. That is not a minor operational detail. It is the signal. 

1. The PICO grid is not bureaucracy. It is the payer map of the indication. 

Regulators approve medicines for indications. Payers reimburse value in decision-relevant segments. JCA makes that difference visible. The tovorafenib indication spans paediatric low-grade glioma with BRAF fusion or rearrangement, or BRAF V600 mutation, following progression after prior systemic therapy. The JCA scope then disaggregates that indication into populations, comparators, and outcomes. In other words, it turns one launch story into multiple reimbursement questions. 

This matters because companies often prepare for the indication while HTA bodies prepare for the decision problem. The PICO framework forces the tension into the open. A broad label may be clinically coherent and regulatorily acceptable, but it does not automatically create a single defendable access narrative. Each PICO asks a different question: for which patients, against which comparator, on which outcomes, and with what certainty? 

The first learning is therefore not simply that the first JCA had many PICOs. It is that the PICO architecture exposes the internal fragility of the evidence package. It shows which parts of the label can survive comparative scrutiny and which parts cannot yet be populated with evidence at all. 

The PICO grid does not merely organise the assessment. It reveals how European payers fragment a regulatory label into reimbursement-relevant questions. 

2. The empty cells are not a failure of process. They are a diagnosis of modern evidence scarcity. 

It would be too easy to call the empty grid a failure. In rare paediatric oncology, molecularly defined tumours and relapsed or refractory settings, the evidence landscape is often structurally thin. Randomised head-to-head trials may be unrealistic, external controls may be small or poorly aligned, and published comparator data may not match the population, line of therapy, endpoint definition, or assessment schedule required by HTA. 

That is precisely why the first JCA is interesting. It does not show that the system is broken. It shows what the system now makes visible. The framework asks the right comparative questions, but the evidence base for modern targeted therapies may often be unable to answer them at all or sufficiently (for PICO 7, comparative data were submitted, but the assessors excluded it because the comparator study was documented only in conference abstracts – insufficient, in their judgement, for a reliable assessment, even in a rare paediatric setting). This pattern is unlikely to be unique to tovorafenib. It will recur in rare diseases, paediatric indications, tumour-agnostic or mutation-defined oncology, and other innovation spaces where clinical development is necessarily small and fragmented. 
 
For pharmaceutical strategists, the empty grid should therefore be read as an evidence map. It tells us where comparative evidence exists, where it is absent, where evidence synthesis is being stretched, and where national access teams will have to rebuild the value story downstream. 

3. One fragile comparison can still become a powerful national anchor. 

The most uncomfortable part of the tovorafenib JCA is not simply the absence of evidence across most PICOs. It is the asymmetry created by the one comparison that does exist. In PICO 5, the JCA includes an unanchored matching-adjusted indirect comparison against dabrafenib plus trametinib. The progression-free survival result is directionally unfavourable to tovorafenib, with a base-case hazard ratio of 4.88 and an effective sample size of 5.81. The report is careful about uncertainty: the analysis is unanchored, the sample is tiny, p-values are nominal, residual confounding is likely, and the effect estimates should not necessarily be interpreted as causal. 

Methodologically, those caveats matter. Commercially, they may not be enough. A fragile estimate can become a strong anchor once it enters national HTA processes, payer negotiations, committee papers and reimbursement dossiers. The nuance stays in the report, the headline travels. The caveats attenuate, the hazard ratio persists. 

The safety comparison reinforces this logic and may, in practice, prove even harder to manage. The JCA reports an odds ratio of 12.65 for severe adverse events (CTCAE Grade 3 or higher) with tovorafenib versus dabrafenib plus trametinib, based on an effective sample size of 14.26 and a nominal p-value of 0.004. Two treatment-related deaths occurred in the tovorafenib arm and none in the comparator arm. These results carry the same methodological qualifications as the efficacy data: unanchored indirect comparison, small numbers, no formal hypothesis testing, residual confounding of unknown magnitude and direction. But a double-digit odds ratio for severe toxicity in a paediatric population, accompanied by a signal on treatment-related mortality, is precisely the kind of finding that national decision-makers are unlikely to treat with methodological detachment. In benefit-risk discussions for children, safety signals carry disproportionate weight, and the emotional and clinical gravity of the numbers will almost certainly outpace the statistical caveats. For a company, this means that the downstream anchoring risk is not limited to efficacy. It extends to the safety narrative, and the two will interact: an unfavourable PFS comparison combined with a severe-AE signal creates a compounding reimbursement problem that is harder to contextualise than either finding alone. 

This is the central downstream risk of JCA. The process may produce highly qualified comparative statements, but national stakeholders may use them with less qualification than the assessors intended. For a company, it is therefore not sufficient to explain why the analysis is uncertain. It must also explain why uncertainty does not mean inferiority, why the comparator frame may be incomplete, why the safety profile must be read in the context of the disease, the treatment alternatives and the formulation, and where the product should realistically sit in clinical sequencing. 

In national reimbursement discussions, uncertainty rarely restores value. More often, it becomes restriction, discount, registry obligation, or delay. 

4. JCA harmonises the evidence record, not the reimbursement outcome. 

The EU HTA Regulation was designed partly to reduce duplication and create a common clinical assessment. But a common clinical assessment is not a common appraisal, and certainly not a common price. The tovorafenib case illustrates this distinction very clearly. The JCA creates a shared European evidence record: the empty cells, the single fragile comparison, the methodological caveats, the outcomes that could not be compared, and the residual uncertainty. What happens next remains national. 

Germany will assess added benefit against the appropriate comparator therapy. France will translate the same evidence into its dual appraisal of medical benefit and improvement in medical benefit. Sweden will run the uncertainty through a cost-effectiveness model and a willingness-to-pay assessment. Italy and Spain will each bring their own institutional logic – national pricing negotiation, managed-entry agreements, regional procurement dynamics – and smaller markets will do the same, shaped by local clinical practice, budget-impact thresholds, and willingness to accept uncertainty in rare paediatric disease. 

That is why the empty grid is not the end of the story. It is the beginning of several national stories. Where the JCA has no comparative result, national HTA bodies retain room to define the comparator, interpret the single-arm evidence, demand real-world evidence, restrict use, or accept a pragmatic unmet-need argument. Where the JCA does have a result, particularly an unfavourable or ambiguous one, national teams must be ready to manage the anchor before it hardens into the reimbursement narrative. 

5. The whitespace is not a consolation prize. It is the strategic battlefield. 

The most commercially important part of a near-empty JCA report may be what it does not say. In the tovorafenib case, the absence of robust comparative results for several populations does not automatically equal defeat. It creates whitespace. But whitespace only becomes opportunity if the company has prepared for it. 

That preparation is not generic. It requires a country-specific evidence strategy: real-world data plans, clinician and patient input, endpoint justification, sequencing logic, prior-therapy mapping, external-control feasibility, and clear narratives for why the relevant clinical question in national practice may differ from the most damaging PICO comparison. For BRAF fusion or rearrangement patients, for example, the absence of a strong JCA comparative conclusion may leave national room to argue unmet need, biological rationale, treatment burden, formulation, sequencing, or lack of suitable alternatives. But those arguments must be built deliberately – they will not emerge from the JCA by themselves. 

The same applies to the comparator story. If tovorafenib and dabrafenib plus trametinib are not always competing in the same real-world treatment position, that has to be demonstrated, not asserted. Treatment sequencing becomes a value argument. Prior exposure becomes a reimbursement argument. The national dossier must correct, refine, or contextualise the PICO frame before the national committee locks it in. 

6. The strategic lesson: JCA readiness starts before the scope is final. 

The first JCA teaches a simple but uncomfortable lesson: European launch strategy can no longer be treated as a downstream adaptation of the regulatory package. JCA readiness is not a submission exercise. It is an evidence, sequencing, and reimbursement strategy discipline. 

Companies need to anticipate the likely PICO grid years before launch. They need to identify which cells are evidence-rich, which are evidence-poor, which comparators are strategically dangerous, which outcomes will be accepted by regulators but challenged by HTA bodies, and which national systems will use the JCA output most aggressively. They also need a plan for the empty cells: what evidence can be generated, what uncertainty can be accepted, what restrictions are tolerable, what registry commitments are credible, and what value story remains defensible country by country. 

This is not about lowering evidence standards. It is about developing a more explicit doctrine for decision-making under endemic evidence scarcity. Rare, paediatric and molecularly targeted therapies will often arrive with evidence packages that are clinically meaningful but HTA-fragile. The winners will not be those who hope the JCA produces a clean European answer. They will be those who understand the map, identify the traps, and prepare the national value defence before the report is published. 

Conclusion: the empty grid is a briefing 

The first EU JCA is exciting not because it creates a harmonised reimbursement answer. It does not – and was never intended to.. It is exciting because it creates a harmonised evidence map. For tovorafenib, that map shows many blank cells, one fragile and potentially damaging comparison, and a large amount of national strategic work still to be done. 

That should not be read as a criticism of one company or one product. It should be read as a signal of the new European access reality. The JCA will publicly reveal where the launch story is robust, where it is uncertain, and where it must be rebuilt in national context. 

For companies developing rare, paediatric or molecularly targeted therapies, the message is clear: the JCA is not the finish line. It is the new starting point for national value defence. The empty grid is not a disappointment. It is a briefing. 

Kintiga takeaways 

• Prepare for the PICO grid, not only for the regulatory indication. 
• Treat absent comparative evidence as a strategic risk and an opportunity requiring a national plan.
• Do not assume methodological caveats will protect against downstream anchoring of unfavourable estimates. 
• Translate JCA outputs into country-specific value defence, sequencing narratives and evidence-generation commitments. 
• Start JCA and national HTA readiness before the scope is final- after publication, the narrative is already public. 

Glossary of terms: 

• AE: Adverse event
• BRAF: v-Raf murine sarcoma viral oncogene homologue B (a proto-oncogene encoding a serine/threonine-protein kinase in the MAPK signalling pathway)
• CTCAE: Common Terminology Criteria for Adverse Events
• EU: European Union
• HTA: Health technology assessment
• HTACG: Member State Coordination Group on Health Technology Assessment
• JCA: Joint clinical assessment
• LGG: Low-grade glioma
• MAIC: Matching-adjusted indirect comparison
• PFS: Progression-free survival
• PICO: Population, Intervention(s), Comparator(s), Outcomes
• V600E: A specific missense mutation at codon 600 of the BRAF gene (valine to glutamic acid substitution)
  
  

Sources:

• Member State Coordination Group on Health Technology Assessment. Joint Clinical Assessment Report of Tovorafenib, Version 1.0. European Union, Brussels, 2026. Endorsed by the Coordination Group pursuant to Article 12(2) of Regulation (EU) 2021/2282 on 30 April 2026. Available at: https://health.ec.europa.eu/document/download/395c2ba0-849a-4f3b-9251-aa2495b3efd7_en?filename=HTA_20260507_TEST_JCA_report_Ojemda_en.pdf
• Member State Coordination Group on Health Technology Assessment. Joint Clinical Assessment Summary Report of Tovorafenib, Version 1.0. European Union, Brussels, 2026.
  Available at: https://health.ec.europa.eu/document/download/1aa5dab6-6c43-4692-91b9-c50e96a6679a_en?filename=hta_jca_mp_202406_tovorafenib_summary-report_en.pdf
• Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment and amending Directive 2011/24/EU. OJ L 458, 22.12.2021, pp. 1-32. Available at: https://eur-lex.europa.eu/eli/reg/2021/2282/oj/eng
• Kilburn LB, Kline C, Landi D, et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2023;29:2752-2761. doi:10.1038/s41591-023-02668-y. Available at: com
• European Medicines Agency. Ojemda (tovorafenib): EPAR – Public Assessment Report. EMEA/H/C/006140. London/Amsterdam: EMA; 2026. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/ojemda
• Bouffet E, Hansford JR, Garré ML, et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med. 2023;389(12):1108-1120. (Comparator study included in the JCA for PICO 5.) Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2303815
• National Centre for Pharmacoeconomics (NCPE), Ireland. Major milestone under the EU HTA Regulation: First Joint Clinical Assessment of benefit complete. Press release, 4 May 2026. Available at: https://www.ncpe.ie/major-milestone-under-the-eu-hta-regulation/
• European Commission, Directorate-General for Health and Food Safety. Joint Clinical Assessments: Implementation of the Regulation on health technology assessment. Available at: https://health.ec.europa.eu/…/joint-clinical-assessments_en